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Transfecting tissue models with CRISPR/Cas9
plasmid DNA using peptide dendrimers†
Susanna J. Zamolo, Tamis Darbre * and Jean-Louis Reymond *
There is currently a lack of efficient reagents to transfect cells with
large plasmid DNA, which would be enabling tools for gene editing
using CRISPR/Cas9 technology. Herein, we report the discovery of
peptide dendrimer Z22 as a non-viral vector for transfecting large
CRISPR/Cas9 pDNA into 3D-tumor spheroids with exceptionally
high efficiency, low cytotoxicity and low immunogenicity.
Gene editing using clustered regularly interspaced short palin-
dromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9)
has revolutionized biology and provides fascinating opportu-
nities as a therapeutic tool.1–3 One of the key challenges in this
technology is to deliver CRISPR/Cas9 plasmid DNA (pDNA) into
the target cells because the plasmid is relatively large, limiting
the use of viral vectors such as adeno-associated virus (AAV) due
to their low encapsulation capacity.4,5 Non-viral vectors, typi-
cally consisting of cationic lipids or polycationic polymers,
should be better suited to deliver CRISPR/Cas9 pDNA because
they can accept larger payloads, while having generally a better
safety profile in terms of cytotoxicity and immunogenicity and
being easier to manufacture than viral vectors.6 Unfortunately
non-viral vectors often have limited tissue penetration,7,8 and
perform only very poorly with pDNA, for example requiring the
use of detached cells by transfection or electroporation when
editing organoids.9,10 Here we focused on transfecting 3D-tumor
spheroids, which present several unique features found in tissues,
such as chemical gradients of oxygen and nutrients at diameters
starting from 200 mm and the production of an extracellular
matrix as a structural and biochemical support.11 Transfecting
such 3D-tumor spheroids is very difficult and has so far only been
achieved with very low efficiency using transfection reagents
based on poly(b-amino ester) and glycogen nanoparticles.12,13
We aimed for a peptide dendrimer14 as a non-viral vector
because dendrimers15–17 and peptide-type oligomers18–20 are
Fig. 1 Synthesis and structure of peptide dendrimer Z22. Conditions:
(a) (i) Fmoc-amino acid (5 equiv./coupling site), oxyma (5 equiv.), DIC
(5 equiv.) in DMF, 1–5 min, 75–90 1C; (ii) piperidine/DMF (1 : 4, v/v),
2 min, 75–90 1C; (iii) P(PPh3)4 (0.25 equiv./alloc group), (CH3)2NHBH3
(25 equiv./alloc group), 2  60 min, 25 1C; (iv) stearic acid (5 equiv.), DIC
(5 equiv.), oxyma (5 equiv.) in NMP, 60 min-overnight; (v) TFA (94%),
i-Pr3SiH (2.5%), DODT (2.5%), H2O (1%), 5 h, 25 1C. (b) Reversed phase
C18 preparative HPLC, gradient 0–70% CH3CN/H2O/0.1% TFA over
45 min.
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both known to be favorable for this task. Specifically, we set out to
obtain a peptide dendrimer for pDNA transfection by combining a
hydrophobic core similar to the core of peptide dendrimers
DMH13 and DMH18, which we recently reported as single compo-
nent transfection reagents for siRNA,21,22 with the branches of
peptide dendrimer G123KL acting as a co-transfection reagent with
lipofectin for DNA,23 siRNA24,25 and oligonucleotides.26
We synthesized peptide dendrimers by standard Fmoc solid-
phase peptide synthesis (SPPS, Fig. 1 and Table 1). We tested
pDNA transfection on HEK293 and HeLa cells using a com-
mercial 9 Kbp ‘‘all-in-one’’ pDNA vector expressing CRISPR/
Cas9 and GFP linked by a self-cleavable 2A peptide,27 together
with a gRNA sequence targeting b-glucuronidase. In this assay
DMH13, DMH18 and G123KL/lipofectin were all less active
than the reference reagent lipofectamine L2000.
An initial series of dendrimers showed a significant trans-
fection level when using one (Z1) or two (Z2) side-chain
stearoylated (C18) lysines as the dendrimer core, while dendri-
mers with other lipidations or buffering histidines at the core
or in the branches were less active or totally inactive (Z3–Z11,
Table S1, ESI†). Transfection improved slightly by adding a core
cysteine residue to Z1 (-Z12) or Z2 (-Z13), but not when
adding a serine (-Z14) or alanine (-Z15). Furthermore, while
inserting a second cysteine reduced transfection (Z12 - Z16),
the disulfide bridged dimer Z17 was slightly more active than
Z12. Following up on both of these compounds, we obtained
a further increase in pDNA transfection efficiency by using
D-enantiomeric residues in the third generation dipeptide
branches (-Z18, Z19). The increase was particularly large with
the full D-enantiomers (-Z20, Z21), which both surpassed
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L2000 — — — 44.5  6.2 34.2  10.0 21.7  1.9 6.6  8.5 85  6.4
DMH13 (kl)8(kkl)4(kll)2k(C16)k(C16) 128.4 (7) 4992.83/
4992.84
28.9  2.1 2.6  2.4 13.1  2.2 0.9  1.3 96  5.6
DMH18 (kl)8(kkl)4(kll)2kllll 73.6 (11) 4712.51/
4712.52
5.8  2.5 0.6  0.3 11.7  2.3 1.8  1.1 91  13
G123KL (KL)8(KKL)4(KKL)2KGSC
f 7.23 (9) 4539.0/
4540.1
8.0  2.7 4.0  1.9 34.8  6.2 2.3  1.3 52  8.6
(1) Optimization of the lipid core:
Z1 (KL)8(KKL)4(KKL)2KK(C18) 8.8 (2) 4684.55/
4684.57
10.7  3.2 2.4  2.2 7.3  1.7 11.3  1.1 64  7.0
Z2 (KL)8(KKL)4(KKL)2KK(C18)K(C18) 1.1 (1) 5078.91/
5078.92
11.7  3.6 2.0  1.4 12.4  2.8 2.3  0.6 79  11
(2) Cysteine insertion
Z12 (KL)8(KKL)4(KKL)2KK(C18)C 1.5 (2) 4787.56/
4787.57
12.0  3.0 3.8  2.5 5.4  1.5 3.8  0.7 80  5.3
Z13 (KL)8(KKL)4(KKL)2KK(C18)K(C18)C 4.4 (3) 5181.92/
5181.93
12.8  2.1 1.4  0.5 7.5  6.9 2.9  0.9 60  10
Z14 (KL)8(KKL)4(KKL)2KK(C18)S 3.6 (3) 4771.59/
4771.60
7.4  1.6 2.1  1.9 6.7  3.5 4.9  0.9 62  6.5
Z15 (KL)8(KKL)4(KKL)2KK(C18)A 8.3 (5) 4755.59/
4755.60
10.1  2.4 1.0  0.9 5.8  5.0 3.0  0.2 71  6.9
Z16 (KL)8(KKL)4(KKL)2KK(C18)CC 5.1 (3) 4890.57/
4890.58
9.5  2.6 1.7  1.0 7.1  1.3 1.1  0.7 62  11
Z17 ((KL)8(KKL)4(KKL)2KK(C18)C)2 1 (1) 9573.11/
9573.10
15.0  5.7 3.5  1.0 11.7  8.6 3.7  0.8 106  12
(3) Stereochemistry and cationic residues
Z18 (kl)8(KKL)4(KKL)2KK(C18)C 5.3 (5) 4787.56/
4787.57
16.7  3.9 2.9  1.1 4.2  2.7 1.7  0.7 70  7.0
Z19 ((kl)8(KKL)4(KKL)2KK(C18)C)2 1.5 (5) 9573.11/
9574.13
15.4  5.6 4.2  2.0 13.7  2.1 3.3  0.7 62  5.6
Z20 (kl)8(kkl)4(kkl)2kk(C18)c 3.1 (5) 4787.56/
4787.57
51.6  12.5 34.2  13.1 10.6  2.1 3.7  1.4 85  8.7
Z21 ((kl)8(kkl)4(kkl)2kk(C18)c)2 3.2 (5) 9573.11/
9573.13
55.0  10.6 37.2  12.6 10.1  4.0 5.0  2.8 63  9.6
Z22 (rl)8(krl)4(krl)2kk(C18)c 7.8 (4) 5179.65/
5179.66
62.5  9.5 47.3  9.3 6.5  1.8 4.7  2.5 83  8.5
a One-letter code amino acids are used, K is the branching lysine residue, C-termini are carboxamide CONH2, and all N-termini are free. Alkyl
chains in the structure are represented by ‘‘C’’ followed by their number of carbon atoms. b Isolated yields as trifluoroacetate salt after preparative
HPLC purification. c ESI-MS, see also the ESI. d Transfection efficiency in HEK and HeLa cells measured as the percentage of GFP positive cells
after 48 h of transfection. Experiments were carried out in triplicate in three independent experiments (N/P 5, 175 pmol of peptide dendrimers in
100 mL Optimem per well, 1.7 mM, 250 ng pDNA). e Fluorescence from intercalation in the pDNA/peptide dendrimer complex at N/P 5 (200 mL, final
concentration of 0.085 nM pDNA and 0.35 mM or 1 mg mL1 L2000) using the Quant-It PicoGreen assay and normalized to the value of pDNA alone.
f Previously published peptide dendrimer as a co-transfection reagent with lipofectin displaying good pDNA transfection efficiency. g Viability and
cytotoxicity assays were performed after 4 h of incubation of HEK cells with peptide dendrimers/pDNA complexes at N/P 5. Cytotoxicity was then
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L2000 in transfection efficiency. Finally, the exhaustive replace-
ment of lysine residues with arginines in Z20 provided Z22,
which transfected up to 62.5% of HEK293 cells and 47.3% of
HeLa cells with the CRISP/Cas9 pDNA vector.
All dendrimers bound pDNA slightly better than L2000 or
G123KL/lipofectin as measured using the picoGreen assay
(Table 1).28 However, there was no correlation between pDNA
binding and transfection efficiency, which is not surprising
considering that the percentage of GFP-positive cells reflects
overall cellular uptake, intracellular pDNA release and protein
expression.
The pDNA/dendrimer complexes did not reduce cell viability
and were not cytotoxic in both cell lines (Table 1 and Table S2,
ESI†). The best transfection dendrimer Z22 was among the least
problematic in the series, and only Z1 showed significant
toxicity but no reduction in cell viability. Additional testing
showed that Z20, Z21 and Z22 preserved their excellent trans-
fection efficiencies and low cytotoxicity at different N/P ratios,
low concentration and in the presence of serum proteins, an
important parameter for potential therapeutic applications
(Fig. S1, ESI†). Furthermore, exposing THP-1 cells, which are
monocytes involved in innate immunity,29 to the dendrimers
alone or with pDNA did not induce any significant release of the
pro-inflammatory cytokines Tumor necrosis factor a (TNF-a) or
interleukin-1b (IL-1b) in comparison to the positive controls LPS30
and PMA.31 We observed a moderate toxicity of the dendrimers on
THP-1 cells; however, the toxic effect was entirely absent in the
presence of 10% serum (Fig. S2, ESI†).
In view of their favourable transfection activities combined
with low toxicity and low immunogenicity, we tested Z20, Z21
and Z22 for transfecting the CRISPR/Cas9 pDNA into 3D tumor
spheroids from HEK cells and quantified transfection by FACS
analysis upon spheroid destruction (Fig. 2a). All three peptide
dendrimers had higher transfection efficiency than L2000, both
in the presence and in the absence of serum proteins, while
also preserving spheroid viability better than L2000 (Fig. 2b).
Transfection was further evidenced by confocal imaging, which
showed that cells throughout the spheroids were efficiently
transfected (Fig. 2c and Fig. S3, ESI†).
To better understand pDNA transfection by our dendrimers,
we further characterized Z20–Z22, as well as Z1 and Z12 as two
less potent analogues. Dynamic light scattering showed that
Fig. 2 Transfection efficiency on HEK spheroids. (a) Schematic representation of spheroid formation and evaluation of transfection. HEK cells were
seeded in a 96-well ultra-low attachment U-bottom plate at 500 cells per well and after two days, spheroids were formed and transfected. 48 h after
transfection, the spheroid size was B250 mm. (b) Transfection efficiency of the best-performing compounds at N/P 5 (175 pmol of peptide dendrimers in
100 mL Optimem per well, 1.7 mM; 250 ng of pDNA per well in 100 mL OptiMEM, 0.42 nM), in the presence and in the absence of 10% FCS. The viability of
HEK spheroids measured after 4 h of incubation with peptide dendrimers/pDNA best-performing complexes at N/P 5 and assessed by the PrestoBlue
reagent. (c) Images of transfected spheroids. Transfected spheroids were imaged via both confocal and light (bright field) microscopies. Spheroids were
fixed and stained with DAPI (blue), anti-GFP conjugated antibody (Alexa-Fluor488, green) and anti-collagen I conjugated antibody (Alexa-Fluor594, red).
Images were taken using a Leica TCS SP8 confocal microscope with lens 10. Scale bar 50 mm. Acquisitions were taken with a step size of 2 mm between


































































































11984 | Chem. Commun., 2020, 56, 11981--11984 This journal is©The Royal Society of Chemistry 2020
dendrimer/pDNA complexes formed large nanoparticles (Rh =
300 nm) at pH 7.4 similar to those formed between pDNA and
the commercial reagents jetPEI or PEI (Fig. S4a, ESI†).32,33
These nanoparticles were only moderately stable as indicated
by zeta potential values close to zero (Fig. S4b, ESI†), and by the
fact that pDNA was readily displaced by heparin (Fig. S5, ESI†).
The dendrimers formed aggregates even in the absence of
pDNA at pH 7.4 at a critical micellar concentration (CMC B
100 mg mL1) corresponding to pDNA complexation as evi-
denced by the Nile Red assay.34 However, the dendrimers were
not aggregated at pH 5.0 corresponding to the acidified endo-
some (Fig. S6, ESI†), and had a different conformation at pH 7.4
and pH 5.0 as evidenced by circular dichroism spectra (Fig. S7,
ESI†). These effects are probably triggered by the protonation
of the eight amino termini, which occurs around pH 6.5 with
such polycationic peptide dendrimers,21,35 leading to increased
positive charge density and electrostatic repulsion between
dendrimers.
These experiments suggest that Z22 and its analogues
mediate pDNA transfection through the same mechanism as
dendrimers DMH13 and DMH18 for siRNA transfection,21,22
despite the very different sizes of their oligonucleotide cargo.
This mechanism involves the aggregation and complexation of
the oligonucleotide at pH 7.4 to form nanoparticles, which
enter cells by endocytosis. Endosome acidification then
induces protonation of the eight amino termini on the peptide
dendrimer, resulting in partial disaggregation and endosome
escape. Indeed, dendrimer mediated pDNA transfection was
entirely blocked by inhibiting endosome acidification with
bafilomycin A1 (Fig. S8, ESI†).
In summary, we identified peptide dendrimer Z22 as an
exceptionally highly efficient reagent for transfecting large pDNA
such as the CRISPR/Cas9 plasmid into cells and 3D-tumor
spheroids, with low cytotoxicity and low immunogenicity. Similar
to related peptide dendrimers,35–38 Z22 is accessible in pure form
by standard SPPS, which greatly facilitates its use.
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